IgG Next Generation is a newly developed polyvalent immunoglobulin preparation for intravenous administration from human plasma for the treatment of immunodeficiencies and autoimmune diseases.
IgG Next Generation has been approved in Germany, Austria and the United Kingdom under the trade name Yimmugo®. In other European countries and in the USA, the approval process has been initiated. Clinical development was successfully completed in two pivotal phase III trials: Study No. 991 for the treatment of patients with primary (congenital) immunodeficiencies (PID) and Study No. 992 for the treatment of patients with immune thrombocytopenia (ITP). The development for further indications is planned